Kymriah, Zellsuspension zur Infusion - Swissmedic Key 66778001 Registration Holder Novartis Pharma Schweiz AG Name Kymriah, Zellsuspension zur Infusion Date of registration 18.10.2018 Introduction of Sequence 18.10.2018 ATC-Classification (L01XL04) Revision date WHO WHO-DDD Valid until Index Therapeuticus (BSV) Show package size Index Therapeuticus (Swissmedic) 07.16.40. Description Swissmedic categorie. A SL Eintrag No Indication Information for professionals IP Consumer information CI Ex-factory-Price PR Deductible k.A. Consumer price PR Feedback FB GTIN 7680667780014 Medication Code Transplantat: Gentherapieprodukt Pharmacode Disponibility
Composition Beutel: tisagenlecleucelum CAR-positive lebensfähige T-Zellen. Enthält genetisch veränderte Zellen 1,2x10e6–6,0x10e8 pro dosi, natrium, chloridum, magnesium, acetas, gluconas, glucosum, 5-hydroxymethylfurfuralum, albuminum, N-acetyltryptophanum natricum, caprylas, aluminium, dextranum 40, dimethylis sulfoxidum, dimethylis sulfonum, q.s. pro 50 ml. Packungsbestandteile Source Data was imported : 08.06.2023
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
